Leadership Team

  • Anya Ragnhildstveit

    Anya Ragnhildstveit

    Chief Executive Officer

    Anya is a clinical research scientist with expertise in child, adolescent, and adult psychiatry. Her work focuses on the safety and therapeutic potential of ketamine, MDMA, and classic psychedelics for treating eating disorders, PTSD, and suicidality.

    Full Biography ↗

  • Paul Seli

    Paul Seli, PhD

    Chief Scientific Officer

    Paul is a Harvard-trained cognitive psychologist and IFS practitioner with expertise in mind wandering, creativity, and mental health. His work examines the cognitive, social, and clinical effects of psychedelics in experimental and naturalistic settings.

    Full Biography ↗

  • Jamarie Geller

    Jamarie Geller, MD

    Chief Clinical Officer

    Jamo is a board-certified psychiatrist, contemplative psychotherapist, and adjunct clinical assistant professor of psychiatry. Her work focuses on ketamine- and psychedelic-assisted psychotherapy for child, adolescent, and adult mental health.

    Full Biography ↗

  • Rachel Pacilio

    Rachel Pacilio, MD

    Chief Medical Officer

    Rachel is a board-certified psychiatrist and clinical assistant professor of psychiatry with expertise in pediatric and perinatal mental health. Her work explores female-specific applications of psychedelics, such as for eating disorders and postpartum depression.

    Full Biography ↗

  • Miriam Kaiyo

    Miriam Kaiyo, PhD

    Chief Impact Officer

    Miriam is a trauma‑informed psychedelic facilitator and human development specialist. Her work centers on ethical, inclusive, and community‑based healing practices that foster spirituality, mental health, and social well-being across the lifespan.

    Full Biography ↗

  • Jonathan Schooler

    Jonathan Schooler, PhD

    Chief Scientific Advisor

    Jonathan is a cognitive scientist and distinguished professor of psychological and brain sciences. His work focuses on the nature of mental life, specifically consciousness, and the effects of psychedelics on subjectivity, brain function, and behavior.

    Full Biography ↗

  • Reid Robison

    Reid Robison, MD, MBA

    Chief Medical Advisor

    Reid is a board-certified psychiatrist, IFS therapist, and adjunct professor of psychiatry with expertise in eating disorders. He has led over 250 clinical trials to date, including pivotal Phase 2 and 3 psychedelic studies sponsored by MAPS, Cybin, and MindMed.

    Full Biography ↗

  • Nathaniel Barr

    Nathaniel Barr, PhD

    Chief Innovation Advisor

    Nate is a cognitive psychologist and professor of creativity and creative thinking. His work examines human nature and mind-manifesting experiences that enable collective transformation through the lenses of psychology, behavior change, and creativity.

    Full Biography ↗